Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43206   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004006-54
    Sponsor's Protocol Code Number:PDY16744
    National Competent Authority:Germany - PEI
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-03-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - PEI
    A.2EudraCT number2020-004006-54
    A.3Full title of the trial
    Phase 2, multicenter, open-label, non-randomized,
    proof-of-concept study evaluating the efficacy, safety,
    and tolerability of BIVV020 in adults with chronic
    inflammatory demyelinating polyneuropathy (CIDP)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Proof-of-concept study for BIVV020 in chronic inflammatory demyelinating polyneuropathy (CIDP)
    A.4.1Sponsor's protocol code numberPDY16744
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSanofi-Aventis Recherche & Développement
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSanofi-Aventis Recherche & Développement
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSanofi-Aventis Deutschland GmbH
    B.5.2Functional name of contact point
    B.5.3.4CountryGermany
    B.5.6E-mailmedinfo.de@sanofi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BIVV020
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    Subcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeBIVV020
    D.3.9.3Other descriptive nameBIVV020
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.3.11.13.1Other medicinal product typeBIVV020 is a humanized monoclonal antibody that binds to and selectively inhibits the activated form of human serine protease complement component 1, s subcomponent (C1s)
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic inflammatory demyelinating
    polyneuropathy
    E.1.1.1Medical condition in easily understood language
    Nervous system diseases
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10077384
    E.1.2Term Chronic inflammatory demyelinating polyneuropathy
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - Part A: Efficacy of BIVV020 across three subpopulations of CIDP patients: standard of care
    (SOC)-Treated, SOC-Refractory and SOC-Naive
    - Part B:Long-term safety and tolerability of BIVV020 in CIDP
    E.2.2Secondary objectives of the trial
    Part A:
    - Safety and tolerability of BIVV020 in CIDP
    - Immunogenicity of BIVV020
    - Efficacy of BIVV020 with overlapping SOC (SOC-Treated group)
    • Part B:
    - Durability of efficacy during long-term treatment with BIVV020 in CIDP
    - Long-term immunogenicity of BIVV020 in CIDP
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Adults ≥18 years of age at the time of signing the informed consent.
    - Documented definite or probable diagnosis of CIDP (typical CIDP, pure motor
    CIDP, or Lewis-Sumner Syndrome) according to the European Federation of Neurological
    Societies (EFNS)/Peripheral Nerve Society (PNS) Task Force first revision.
    - Belonging to one of the following three groups: standard-of-care (SOC)-Treated,
    SOC-Refractory or SOC-Naïve, as defined below.
    - SOC-Treated (all criteria a-c must be met): a) Documented evidence of
    objective response to SOC, with clinically meaningful improvement. Clinically meaningful
    improvement is defined as one of the following: ≥1-point decrease in adjusted INCAT
    score, ≥4 points increase in RODS total score, ≥3 points increase in MRC Sum score, ≥8
    kilopascal improvement in mean grip strength (one hand), or an equivalent improvement
    based on information documented in medical records and per the PI’s judgement. b) Must
    be on stable SOC therapy, defined as no change greater than 10% in frequency or dose
    of immunoglobulin therapy or corticosteroids within 8 weeks prior to screening, remaining
    at stable SOC therapy until the time of first BIVV020 dosing. c) Evidence of clinically
    meaningful deterioration on interruption or dose reduction of SOC therapy within 24
    months prior to screening, determined by clinical examination or medical records.
    Clinically meaningful deterioration is defined as one of the following: ≥1-point increase in
    adjusted INCAT score, decrease in RODS total score ≥4 points, decrease in MRC Sum
    score ≥3, mean grip strength worsening of ≥8 kilopascals (one hand), or an equivalent
    deterioration based on information from medical records and at the PI’s judgement.
    - SOC-Refractory (all criteria a-d must be met): a) Evidence of failure or
    inadequate response to SOC defined as no clinically meaningful improvement and
    persistent INCAT score ≥2 after treatment for a minimum of 12 weeks on SOC prior to
    screening. A clinically meaningful improvement is defined as one of the following: ≥1-point
    decrease in adjusted INCAT score, increase in RODS total score ≥4 points, increase in
    MRC Sum score ≥3, mean grip strength improvement of ≥8 kilopascals (one hand), or
    equivalent improvement based on information from medical records and at the PI’s
    judgement.
    Or
    - Unable to receive or continue treatment with immunoglobulins or corticosteroids
    due to side effects.
    - b) Patient has not received immunoglobulins (IVIg or SCIg) within 12 weeks
    prior to screening. c) Certain immunosuppressant drugs are allowed in this group if taken
    for ≥6 months and at a stable dose for ≥3 months prior to screening: azathioprine,
    methotrexate, mycophenolate mofetil and cyclosporine. Oral corticosteroids are allowed if on a stable dose of <20 mg/day of prednisone (or equivalent dose for other oral
    corticosteroids) for ≥3 months prior to screening. d) INCAT score: 2-9 (a score of 2 should
    be exclusively from leg disability component of INCAT).
    - SOC-Naïve (all criteria a-c must be met): a) Participants without previous
    treatment for CIDP or participants who received immunoglobulins (IVIg or SCIg) or
    corticosteroids but were stopped for reasons other than lack of response or side effects.
    b) Not treated with immunoglobulins (IVIg or SCIg) or corticosteroids for at least 6 months
    prior to screening. c) INCAT score: 2-9 (a score of 2 should be exclusively from leg
    disability component of INCAT.
    - Documented vaccinations against encapsulated bacterial pathogens given
    within 5 years of enrollment or initiated a minimum of 14 days prior to first dose
    - A female participant must use a double contraception method including a highly
    effective method of birth control from inclusion and up to 52 weeks plus 30 days after the
    last study dose and agree not to donate eggs, ova or oocytes during this period.
    - A female participant must have a negative highly sensitive pregnancy test (urine
    or serum) as required by local regulations within 24 hours before the first dose of study
    intervention.
    - Male participants, whose partners are of childbearing potential must accept to
    use, during sexual intercourse, a double contraceptive method according to the following:
    condom plus an additional highly effective contraception
    - Male participants must have agreed not to donate sperm during the intervention
    and up to 52 weeks after the last dose.
    - Capable of giving signed informed consent
    E.4Principal exclusion criteria
    - Polyneuropathy of other causes, including but not limited to hereditary
    demyelinating neuropathies, neuropathies secondary to infection or systemic disease,
    diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy,
    monoclonal gammopathy of uncertain significance, lumbosacral radiculoplexus
    neuropathy, pure sensory CIDP and acquired demyelinating symmetric (DADS)
    neuropathy (also known as distal CIDP).
    - Any other neurological or systemic disease that can cause symptoms and signs
    interfering with treatment or outcome assessments.
    - Poorly controlled diabetes (HbA1c >7%).
    - Serious infections requiring hospitalization within 30 days prior to screening and
    any active infection requiring treatment during screening.
    - Clinical diagnosis of SLE.
    - Sensitivity to any of the study interventions, or components thereof, or drug or
    other allergy that, in the opinion of the Investigator, contraindicates participation in the study. Specifically, history of any hypersensitivity reaction to BIVV020 or its components
    or of a severe allergic or anaphylactic reaction to any humanized or murine monoclonal
    antibody.
    - Participants with a history of suicidality in the six months prior to screening or currently at risk of committing suicide.
    - Presence of conditions (medical history or laboratory assessments) that may
    predispose the participant to excessive bleeding or increased risk of infection.
    - Evidence of CIDP relapse within 6 weeks after receiving a vaccination.
    - A history of CIDP relapse after prior vaccination.
    - Recent or planned major surgery that could confound the results of the trial or
    put the participant at undue risk.
    - Treatment with plasma exchange within 12 weeks prior to screening.
    - Prior treatment with rituximab or ocrelizumab in the 6 months prior to BIVV020
    dosing or until return of B-cell counts to normal levels, whichever is longer.
    - Immunosuppressive/chemotherapeutic medications such as azathioprine,
    methotrexate, cyclophosphamide, cyclosporine, mycophenolate mofetil, tacrolimus,
    interferon, TNF-alpha inhibitor: within 6 months prior to dosing (except for some cases as
    indicated in the SOC-Refractory group).
    - Treatment (any time) with highly immunosuppressive/chemotherapeutic
    medications with sustained effects, eg, mitoxantrone, alemtuzumab, cladribine.
    - Treatment (any time) with total lymphoid irradiation or bone marrow
    transplantation.
    - Use of any specific complement system inhibitor (eg, eculizumab) within 12
    weeks or 5 times the half-life of the product, whichever is longer, prior to screening.
    - Pregnant (defined as positive β-HCG blood test) or lactating females.
    - Positive result on any of the following tests: hepatitis B surface (HBsAg) antigen,
    antihepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies,
    anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2
    antibodies).
    - Evidence of IgG4 autoantibodies against paranodal proteins (NF155 and
    CNTN1).
    E.5 End points
    E.5.1Primary end point(s)
    1) Part A, SOC-Treated: Percentage of
    participants relapsing after withdrawal of SOC
    and during the BIVV020 treatment period:
    Relapse will be defined as ≥1-point increase in adjusted Inflammatory
    neuropathy cause and treatment (INCAT) disability score.
    2) Part A, SOC-Refractory and SOC-Naïve:
    Percentage of participants responding during
    the BIVV020 treatment period: Response will be defined as ≥1-point decrease in adjusted INCAT disability
    score.
    3)Part B: Number of participants reported with
    adverse Events:Number of participants reported with adverse events during 76 weeks of
    treatment and 22 weeks of follow-up.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1)Day 1 up to 24 weeks

    2) Day 1 up to 24 weeks

    3) Day 1 up to Week 98
    E.5.2Secondary end point(s)
    1)Part A: Number of participants reported with
    adverse Events:Number of participants reported with adverse events during 24 weeks of
    treatment period and if not enrolled to Part B, 22 weeks of follow-up period.
    2)Part A: Number of participants with incidence
    and titer of anti-BIVV020 antibodies (ADA):Incidence and titer of anti-BIVV020 antibodies (ADA) will be assessed during the 24 weeks of treatment period and if not enrolled to Part B, 22 weeks of follow-up period.
    3)Part A: Percentage of participants in the SOC Treated
    group improving during the overlap treatment period: Improvement will be defined as ≥1 point decrease in adjusted INCAT
    disability score.
    4)Part B, SOC-Treated: Percentage of
    participants relapse-free during the treatment
    extension period:Relapse-free will be defined as no increase in adjusted INCAT disability
    score >2 points.
    5)Part B, SOC-Refractory and SOC-Naive:
    Percentage of participants with sustained
    response during the treatment extension period:Maintenance of response will be defined as no increase in adjusted INCAT
    disability score >2 points.
    6)Part B: Long-term immunogenicity:Incidence and titer of anti-BIVV020 antibodies during the entire BIVV020
    treatment period and follow-up period.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1)-2) Day 1 up to 46 weeks
    3)Day 1 up to 12 weeks
    4)-5)Week 24 up to Week 76
    6)Day 1 Up to Week 98
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA17
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days17
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial days17
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.2.1Number of subjects for this age range: 98
    F.1.3Elderly (>=65 years) No
    F.1.3.1Number of subjects for this age range: 32
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 90
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Post trial access: In addition to the 18 months of BIVV020 treatment in Parts A and B of this trial, a separate
    open-label extension study may be proposed in which case participants will be offered the
    opportunity to enroll in that study. Details will be provided under a separate protocol.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-03-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-06-23
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA